If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics should suffice.

The company has collaboration with Mirador Therapeutics to advance mirador’s precision medicines for immunology and inflammation. 23andMe Holding Co. was founded in 2006 and is headquartered in ...

On the sidelines of this year’s J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Mark McKenna, CEO of Mirador Therapeutics, a member of ...

Yesterday, the company announced a new R&D partnership with precision medicine company Mirador Therapeutics, granting the biotech a license to use a "targeted set of aggregated, de-identified ...

The company aims to enter the clinic this year. Mirador Therapeutics is not making immunology and inflammation medicines for today. CEO Mark McKenna wants to be the creator of 2030’s great ...

And one startup, Xaira Therapeutics, took it a step further, expanding the industry’s definition of a megaround by reeling in a rarely seen $1 billion financing early in the year. In this week ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...

Piotr Swat / SOPA Images / LightRocket via Getty Images Summit Therapeutics shares dropped 14% Monday as it reported a fourth-quarter adjusted loss nearly double that of the previous year.

Viking Therapeutics (NASDAQ:VKTX) quickly soared 12% amid some renewed takeover speculation for the obesity drug maker. There's some renewed speculation Viking (NASDAQ:VKTX) may be a takeover ...

A digital therapeutics start-up which uses augmented reality (AR) glasses to aid people suffering from disorders including Parkinson's disease and multiple sclerosis will this week announce a £ ...